They also characterized the mutational landscape of tumor DNA in 54 patients with available next-generation sequencing data, and found that a certain number of patients with somatic mutations in CDKN2A or MET (22% and 20%, respectively) tended to have favorable response to cabozantinib. This evidence concerns the gene CDKN2A and neoplasm.